Frank S. Fan- Section of Hematology and Oncology, Department of Medicine, Ministry of Health and Welfare Taitung Hospital, Taitung County, Taiwan
Introduction
Hepatocellular carcinoma (HCC), a leading cause of cancer-related death in the world, was assessed to have a global incidence rate of 9.3 per 100,000 person-years with an approximately equivalent mortality rate of 8.5 in 2018 with substantial variations in different areas (1). The main risk factors for HCC have been attributed to chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcoholic cirrhosis, non-alcoholic fatty liver disease (NAFLD), alfatoxin, and aristolochic acid (2). Despite extensive vaccination for HBV and aggressive administration of anti-viral treatments against HBV and HCV, the International Agency for Research on Cancer reckons that 1,436,744 new patients will be diagnosed to have liver and intrahepatic bile duct cancer in 2040 on the basis of annual projections (3) with 75%-85% as HCC and 10%-15% as intrahepatic cholangiocarcinoma (4). Prevention of HCC and reduction of its death rate therefore become an urgent need in public health.
Interestingly, a recent dose-response meta-analysis disclosed that an extra two-cups of coffee per day reduced the risk of HCC by 35% without significant intervention from liver disease stage, body mass index, alcohol drinking, and viral hepatitis B or C infection (5). The inverse correlation between coffee consumption and HCC risk was shortly supported by another similar dose-response study reporting a 15% reduction in HCC risk by one cup of coffee per day (6). Following these, in a succeeding umbrella review of meta-analyses of observational studies accommodating 36 summary associations for 26 cancer sites, highly suggestive evidence was shown for an inverted relationship between coffee intake and the risk of HCC (7). However, the potential mechanism of coffee’s beneficial effect on reducing HCC development remains to be explicated and requires resolution in spite of thoroughly reviewing relevant literatures (8). Herein, an attempt to explain the causality will be made based on recent advancement of research on inflammasomes, the supramolecular cytoplasmic structures which drive immune responses and inflammation.
The role of inflammation in hepatocarcinogenesis
Regardless of multiple aetiologies for HCC, progressive accumulation of molecular genetic alterations begins in preneoplastic dysplastic nodules resulting from aberrant hepatocyte regeneration (9). Prior to the formation of dysplastic nodules and cirrhosis, the liver has sustained chronic inflammation stimulated by endoplasmic reticulum (ER) stress induced by a variety of pathogenic factors (10). Among them, alcoholic steatohepatitis (ASH), NAFLD, chronic viral hepatitis B and C are most notable ones in which HCC always develops as a final outcome from a progressive process through inflammation to fibrosis and subsequent cirrhosis (11). In addition to ER stress, inflammasomes activation elicited by various pathogen- and danger-associated molecular patterns (12) might also play essential roles in generating inflammatory signalling cascades in inflammation-based hepatocarcinogenesis. The interaction between ER stress and inflammasomes is complex. Accumulating evidence shows that ER stress probably exerts its function through activating inflammasomes (13, 14) and promoting inflammatory process induced by inflammasomes (15).
Inflammasomes, the dominant pathway of inflammation and the pro-caspase-1 activating platforms, are cytoplasmic organelles containing one of the five pattern-recognition receptors, that is, the nucleotide-binding oligomerization domain (NOD), leucine-rich repeat-containing proteins family members NLRP1, NLRP3, and NLRC4, as well as absent-in-melanoma 2 (AIM2) and pyrin (16). Activation of inflammasomes leads to augmentation of caspases, resulting in apoptosis, pyroptosis, release of proinflammatory cytokine interleukin-1β (IL-1β) and interleukin-18 (IL-18) (17). The NLRP3 inflammasome which comprises NOD-like receptor family pyrin domain-containing 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1 cooperates with ER stress and mitochondria damage in the pathogenesis of many liver disorders such as ASH, NAFLD, nonalcoholic steatohepatitis (NASH), hepatic ischemic injury, and hepatotoxicity (18, 19). Moreover, experimental research has demonstrated that deubiquitination and activation of NLRP3 inflammasome facilitates HCV life cycle in HCV-infected hepatic cells (20) and HBV X antigen activates NLRP3 inflammasome under oxidative stress and advances pyroptosis in hepatic cells (21). Notably, the pyroptosis mediated by inflammasomes also takes part in the pathogenesis of chronic virus infection and liver fibrosis, affecting hepatocytes, Kupffer cells, hepatic stellate cells, and inflammatory cells as a whole (22).
Therefore, inhibition of inflammasomes and the resulting pyoptosis has become hopeful therapeutic strategy for ameliorating HCC pathogenesis from a variety of aetiologies including alcoholic hepatitis, fatty liver and viral hepatitis, by attacking cell death and tumor microenvironment (23). Meanwhile, numerous chemical agents and botanic drugs have been intensively tested as inhibitors for NLRP3 inflammasome and its constituents as effective modalities in prevention of HCC development from precedent hepatitis, fibrosis, and cirrhosis (24, 25). Nevertheless, a common drink, coffee, has long been overlooked in regard of the purpose mentioned above.
Caffeine inhibits NLRP3 inflammasome activation
The capability of inhibiting NLRP3 inflammasome by caffeine has been revealed in several recent experimental cell and animal models. First of all, caffeine seems capable to protect the central nervous system from various insults by NLRP3 inflammasome inhibition. Caffeine is able to improve microglial polarization and long-term cognitive function in neonatal rats with hypoxic-ischemic white-matter damage through adenosine A2a receptor (A2aR)-mediated inhibition of NLRP3 inflammasome activation (26). Attenuation of microglia-mediated neuroinflammation in experimental autoimmune encephalomyelitis can also be achieved by caffeine with promotion of autophagy and inhibition of NLRP3 inflammasome activation in microglia (27). Sepsis-associated encephalopathy could be well protected by caffeine via inhibition of the uncoupling protein 2-mediated NLRP3 inflammasome pathway, leading to decreased neuronal apoptosis and mitochondrial dysfunction in astrocytes (28). In other systems, a study in neonatal mice discloses that caffeine can lower apoptosis of type 2 alveolar epithelial cells, preventing hypoxia-induced lung injury, through inhibition of NLRP3 inflammasome and NF-κB pathway (29). Another investigation in lipopolysaccharide-induced macrophages from human monocyte leukaemia cell line reveals that caffeine inhibits NLRP3 inflammasome activation, and thus decreasing secretion of IL-1β and IL-18, by suppressing mitogen-activated protein kinase/NF-κB signalling and A2aR-associated reactive oxygen species production (30). No wonder, it has been proposed that inhibition of inflammasome activation by caffeine with the consequent anti-inflammation and anti-pyroptosis effects probably could provide beneficial effects in fighting against SARS-CoV-2 infection (31) and ageing (32).
A hypothesis for the mechanism of coffee’s chemopreventive effects on hepatocellular carcinoma
The integration of all the information above logically leads to a hypothesis that the positive effect of coffee in decreasing the risk of HCC derives from caffeine’s capability of inhibiting NLRP3 inflammasome activation. To put it another way, alleviating chronic inflammation process in the liver by drinking coffee can substantially lead to a reduced incidence of HCC. This speculation seems to be compatible with the facts that coffee consumption reduces not only the incidence of liver cancer but also risks of chronic liver disease and cirrhosis (33). It is hoped that the protective efficacy of caffeine against HCC could be demonstrated clearly by carefully designed animal experiments in the near future. Upon waiting definite research results, nonetheless, other possible mechanisms regarding caffeine’s beneficial influence on inflammation and carcinogenesis ought to be discussed as well.
Discussion
As everybody may know, type 2 taste receptors (TAS2Rs), the bitter taste-sensing receptors, distribute widely in human organs and, once stimulated, have unidentified anticancer activity (34). It has been proved that several TAS2Rs exist in murine hepatocyte cell line (35). In addition to its presumed anti-inflammatory effects through acting on TAS2R and A2aR (and thus contributing to mitigating HCC pathogenesis) (36), caffeine probably also has unknown anticancer effects through activation of TAS2Rs. It is worthy to note that caffeine does have the capability of inhibiting human liver cancer cells in the laboratory (37). However, before going too quick to a conclusion, we have to recognize the fact that the inverse association with coffee consumption is less clear in caners arising from oesophagus, pancreas, kidneys, bladder, colorectum, ovaries, and prostate due to conflicting results or statistically nonsignificant data (38).
There are more than one thousand bioactive components in brewed coffee and the key beneficial compounds are attributed to polyphenolic agents, including caffeine, cafestol, kahweol, and chlorogenic acid (38). Although the diterpenes, cafestol and kahweol, have been demonstrated to have anti-inflammation and anti-carcinogenesis effects (39), they are present only in minimal amounts in instant and filtered coffee, which, however, seem also to have preventive effects on HCC (5). The chlorogenic acid, on the other hand, have been found to have the ability of inhibiting inflammasome NLRP3 activation in a variety of experimental models (40–42) and should therefore become another potential candidate of research interest in addition to caffeine in this regard.
Anyway, in accord with the hypothesis raised here, a lot of chemical agents and herb drugs besides caffeine have been examined in animal studies to see whether some of them could be used as the adequate medicine to attenuate inflammasome activity and slow the progress of alcohol-associated liver disease (43, 44), high-fat diet-associated liver disease (45–48), fulminant hepatitis (49), and acute liver injury (50). Although we highly suggested that caffeine be tested for similar objectives according to its ability of inhibiting NLRP3 inflammasome activation, caffeine has its own adverse effects when consumed too much, for example, increasing blood pressure, inducing anxiety, reducing skeletal-muscle insulin sensitivity, and decreasing infant birth weights (51). Moderate doses of coffee (40-200 mg per day) are thus recommended by health experts (52).
Conclusions
Epidemiology data point out confidently that coffee drinking is inversely correlated with the incidence of HCC. Caffeine has been proved to be able to inhibit NLRP3 inflammasome activation in a series of cellular and animal studies. A hypothesis is raised here that the mechanism of coffee’s beneficial effects on prevention of HCC relies on the capability of caffeine in suppressing NLRP3 inflammasome activation and the ensuing inflammatory process, pyroptosis, hepatic fibrosis, and cirrhosis. Other mechanisms might exit also and the hypothesis needs further laboratory work and clinical trials to confirm. Having a habit of drinking coffee, of course, cannot guarantee a healthy liver without maintaining healthy life styles.
Author contributions
FF alone conceptualized the idea, collected the literature, retrieved the database in the internet, and wrote the whole paper. The author confirms being the sole contributor of this work and has approved it for publication.
Acknowledgments
The author likes to express his appreciation to the librarian Miss Wenyi Shaw, who works in the Ministry of Health and Welfare Changhua Hospital, Taiwan, for her help in retrieving scientific articles necessary for constructing the hypothesis in this paper.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology (2021) 73(Suppl 1):4–13. doi: 10.1002/hep.31288
2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol (2019) 16(10):589–604. doi: 10.1038/s41575-019-0186-y
3. International Agency for Research on Cancer. Estimated number of new cases from 2020 to 2040, incidence, both sexes, age [0-85+], liver and intrahepatic bile ducts, in: Cancer tomorrow (2022). Available at: https://gco.iarc.fr/tomorrow/en/dataviz/tables?cancers=11 (Accessed September 9, 2022).
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
5. Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open (2017) 7(5):e013739. doi: 10.1136/bmjopen-2016-013739
6. Godos J, Micek A, Marranzano M, Salomone F, Rio DD, Ray S. Coffee consumption and risk of biliary tract cancers and liver cancer: A dose-response meta-analysis of prospective cohort studies. Nutrients (2017) 9(9):950. doi: 10.3390/nu9090950
7. Zhao LG, Li ZY, Feng GS, Ji XW, Tan YT, Li HL, et al. Coffee drinking and cancer risk: an umbrella review of meta-analyses of observational studies. BMC Cancer (2020) 20(1):101. doi: 10.1186/s12885-020-6561-9
8. Inoue M, Tsugane S. Coffee drinking and reduced risk of liver cancer: Update on epidemiological findings and potential mechanisms. Curr Nutr Rep (2019) 8(3):182–6. doi: 10.1007/s13668-019-0274-1
9. Villanueva A. Hepatocellular carcinoma. N Engl J Med (2019) 380(15):1450–62. doi: 10.1056/NEJMra1713263
10. Wei J, Fang D. Endoplasmic reticulum stress signaling and the pathogenesis of hepatocarcinoma. Int J Mol Sci (2021) 22(4):1799. doi: 10.3390/ijms22041799
11. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res (2021) 149:1–61. doi: 10.1016/bs.acr.2020.10.001
12. Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis (2019) 10(2):128. doi: 10.1038/s41419-019-1413-8
13. Chen X, Guo X, Ge Q, Zhao Y, Mu H, Zhang J. ER stress activates the NLRP3 inflammasome: A novel mechanism of atherosclerosis. Oxid Med Cell Longev (2019) 2019:3462530. doi: 10.1155/2019/3462530
14. Lv S, Li X, Wang H. The role of the effects of endoplasmic reticulum stress on NLRP3 inflammasome in diabetes. Front Cell Dev Biol (2021) 9:663528. doi: 10.3389/fcell.2021.663528
15. Chong WC, Shastri MD, Peterson GM, Patel RP, Pathinayake PS, Dua K, et al. The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders. Clin Transl Immunol (2021) 10(2):e1247. doi: 10.1002/cti2.1247
16. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci (2019) 20(13):3328. doi: 10.3390/ijms20133328
17. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discovery (2020) 6:36. doi: 10.1038/s41421-020-0167-x
18. Lu X, Huang H, Fu X, Chen C, Liu H, Wang H, et al. The role of endoplasmic reticulum stress and NLRP3 inflammasome in liver disorders. Int J Mol Sci (2022) 23(7):3528. doi: 10.3390/ijms23073528
19. Torres S, Segalés P, García-Ruiz C, Fernández-Checa JC. Mitochondria and the NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis. Cells (2022) 11(9):1475. doi: 10.3390/cells11091475
20. Ramachandran A, Kumar B, Waris G, Everly D. Deubiquitination and activation of the NLRP3 inflammasome by UCHL5 in HCV-infected cells. Microbiol Spectr (2021) 9(1):e0075521. doi: 10.1128/Spectrum.00755-21
21. Xie WH, Ding J, Xie XX, Yang XH, Wu XF, Chen ZX, et al. Hepatitis b virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation. Inflamm Res (2020) 69(7):683–96. doi: 10.1007/s00011-020-01351-z
22. Yang H, Wang J, Liu ZG. Multi-faceted role of pyroptosis mediated by inflammasome in liver fibrosis. J Cell Mol Med (2022) 26(10):2757–65. doi: 10.1111/jcmm.17277
23. García-Pras E, Fernández-Iglesias A, Gracia-Sancho J, Pérez-Del-Pulgar S. Cell death in hepatocellular carcinoma: Pathogenesis and therapeutic opportunities. Cancers (Basel) (2021) 14(1):48. doi: 10.3390/cancers14010048
24. Zhao N, Li CC, Di B, Xu LL. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors. J Autoimmun (2020) 113:102515. doi: 10.1016/j.jaut.2020.102515
25. Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, et al. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: Therapeutic targets and treatment. Front Pharmacol (2022) 13:780496. doi: 10.3389/fphar.2022.780496
26. Yang L, Yu X, Zhang Y, Liu N, Xue X, Fu J. Caffeine treatment started before injury reduces hypoxic-ischemic white-matter damage in neonatal rats by regulating phenotypic microglia polarization. Pediatr Res (2022). doi: 10.1038/s41390-021-01924-6
27. Wang HQ, Song KY, Feng JZ, Huang SY, Guo XM, Zhang L, et al. Caffeine inhibits activation of the NLRP3 inflammasome via autophagy to attenuate microglia-mediated neuroinflammation in experimental autoimmune encephalomyelitis. J Mol Neurosci (2022) 72(1):97–112. doi: 10.1007/s12031-021-01894-8
28. Hu J, Cheng Y, Chen P, Huang Z, Yang L. Caffeine citrate protects against sepsis-associated encephalopathy and inhibits the UCP2/NLRP3 axis in astrocytes. J Interferon Cytokine Res (2022) 42(6):267–78. doi: 10.1089/jir.2021.0241
29. Chen S, Wu Q, Zhong D, Li C, Du L. Caffeine prevents hyperoxia-induced lung injury in neonatal mice through NLRP3 inflammasome and NF-κB pathway. Respir Res (2020) 21(1):140. doi: 10.1186/s12931-020-01403-2
30. Zhao W, Ma L, Cai C, Gong X. Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-κB and A2aR signaling in LPS-induced THP-1 macrophages. Int J Biol Sci (2019) 15(8):1571–81. doi: 10.7150/ijbs.34211
31. Romero-Martínez BS, Montaño LM, Solís-Chagoyán H, Sommer B, Ramírez-Salinas GL, Pérez-Figueroa GE, et al. Possible beneficial actions of caffeine in SARS-CoV-2. Int J Mol Sci (2021) 22(11):5460. doi: 10.3390/ijms22115460
32. Aden K, Rosenstiel P. The dark age(ing) of the inflammasome. Immunity (2017) 46(2):173–5. doi: 10.1016/j.immuni.2017.02.009
33. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ (2017) 359:j5024. doi: 10.1136/bmj.j5024
34. Tuzim K, Korolczuk A. An update on extra-oral bitter taste receptors. J Transl Med (2021) 19(1):440. doi: 10.1186/s12967-021-03067-y
35. Kurtz R, Steinberg LG, Betcher M, Fowler D, Shepard BD. The sensing liver: Localization and ligands for hepatic murine olfactory and taste receptors. Front Physiol (2020) 11:574082. doi: 10.3389/fphys.2020.574082
36. Liu L, Zhang C, Chen J, Li X. Rediscovery of caffeine: An excellent drug for improving patient outcomes while fighting WARS. Curr Med Chem (2021) 28(27):5449–62. doi: 10.2174/0929867327666201103162810
37. Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol (2008) 102(6):543–51. doi: 10.1111/j.1742-7843.2008.00231.x
38. Pauwels EKJ, Volterrani D. Coffee consumption and cancer risk: An assessment of the health implications based on recent knowledge. Med Princ Pract (2021) 30(5):401–11. doi: 10.1159/000516067
39. Ren Y, Wang C, Xu J, Wang S. Cafestol and kahweol: A review on their bioactivities and pharmacological properties. Int J Mol Sci (2019) 20(17):4238. doi: 10.3390/ijms20174238
40. Shi A, Shi H, Wang Y, Liu X, Cheng Y, Li H, et al. Activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation contribute to the protective effect of chlorogenic acid on acute liver injury. Int Immunopharmacol (2018) 54:125–30. doi: 10.1016/j.intimp.2017.11.007
41. Zeng J, Zhang D, Wan X, Bai Y, Yuan C, Wang T, et al. Chlorogenic acid suppresses miR-155 and ameliorates ulcerative colitis through the NF-κB/NLRP3 inflammasome pathway. Mol Nutr Food Res (2020) 20:e2000452. doi: 10.1002/mnfr.202000452
42. Zeng J, Wan X, Liu T, Xiong Y, Xiang G, Peng Y, et al. Chlorogenic acid ameliorates Klebsiella pneumoniae-induced pneumonia in immunosuppressed mice via inhibiting the activation of NLRP3 inflammasomes. Food Funct (2021) 12(19):9466–75. doi: 10.1039/d0fo03185b
43. Osna NA, Eguchi A, Feldstein AE, Tsukamoto H, Dagur RS, Ganesan M, et al. Cell-to-Cell communications in alcohol-associated liver disease. Front Physiol (2022) 13:831004. doi: 10.3389/fphys.2022.831004
44. Li F, Zhao C, Shao T, Liu Y, Gu Z, Jiang M, et al. Cathelicidin-related antimicrobial peptide alleviates alcoholic liver disease through inhibiting inflammasome activation. J Pathol (2020) 252(4):371–83. doi: 10.1002/path.5531
45. Saha M, Manna K, Das Saha K. Melatonin suppresses NLRP3 inflammasome activation via TLR4/NF-κB and P2X7R signaling in high-fat diet-induced murine NASH model. J Inflamm Res (2022) 15:3235–58. doi: 10.2147/JIR.S343236
46. Kanno K, Koseki M, Chang J, Saga A, Inui H, Okada T, et al. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. Sci Rep (2022) 12(1):2996. doi: 10.1038/s41598-022-06542-8
47. Zhang H, Gao X, Chen P, Wang H. Protective effects of tiaoganquzhi decoction in treating inflammatory injury of nonalcoholic fatty liver disease by promoting CGI-58 and inhibiting expression of NLRP3 inflammasome. Front Pharmacol (2022) 13:851267. doi: 10.3389/fphar.2022.851267
48. Xiang R, Liu Y, Fan L, Jiang B, Wang F. RNA Adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. Lab Invest (2022) 102(10):1088–100. doi: 10.1038/s41374-022-00805-8
49. Xia Y, Wang P, Yan N, Gonzalez FJ, Yan T. Withaferin a alleviates fulminant hepatitis by targeting macrophage and NLRP3. Cell Death Dis (2021) 12(2):174. doi: 10.1038/s41419-020-03243-w
50. Zhao J, He B, Zhang S, Huang W, Li X. Ginsenoside Rg1 alleviates acute liver injury through the induction of autophagy and suppressing NF-κB/NLRP3 inflammasome signaling pathway. Int J Med Sci (2021) 18(6):1382–89. doi: 10.7150/ijms.50919
51. van Dam RM, Hu FB, Willett WC. Coffee, caffeine, and health. N Engl J Med (2020) 383(4):369–78. doi: 10.1056/NEJMra1816604
Keywords: caffeine, coffee, hepatocellular carcinoma, NLRP3 inflammasome, pyroptosis
Citation: Fan FS (2022) Coffee reduces the risk of hepatocellular carcinoma probably through inhibition of NLRP3 inflammasome activation by caffeine. Front. Oncol. 12:1029491. doi: 10.3389/fonc.2022.1029491
Received: 27 August 2022; Accepted: 03 October 2022;
Published: 18 October 2022.
Edited by:
Federico Ravaioli, University of Bologna, ItalyReviewed by:
Xiaojie Gan, Naval Medical University, ChinaCopyright © 2022 Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frank S. Fan, fantast.fan@msa.hinet.net
†ORCID: Frank S. Fan, orcid.org/0000-0002-8123-6941